Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06464068
Title AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC)
Acronym DURVASCC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gruppo Oncologico Italiano di Ricerca Clinica
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA

Facility Status City State Zip Country Details
AUSL-IRCCS of Reggio Emilia RECRUITING Reggio Emilia 42123 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field